Sharon Townson
Directeur Technique/Scientifique/R&D chez MONTE ROSA THERAPEUTICS, INC.
Fortune : - $ au 31/05/2024
Postes actifs de Sharon Townson
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2021 | - |
| Corporate Officer/Principal | 01/07/2020 | 01/12/2020 |
Historique de carrière de Sharon Townson
Anciens postes connus de Sharon Townson
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| KYMERA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/04/2019 | 01/06/2020 |
| Corporate Officer/Principal | 01/04/2019 | 01/06/2020 | |
Warp Drive Bio, Inc.
 Warp Drive Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Warp Drive Bio, Inc. focused on proprietary genomic technology to discover drugs of natural origin. The firm deployed proprietary platforms Genome Mining and Small Molecule Assisted Receptor Targeting (SMART) to discover and develop novel molecules addressing new pharmacologic mechanisms. The company was founded by Gregory L. Verdine, George McDonald Church, and James A. Wells in 2012 and was headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/06/2013 | 01/12/2018 |
Formation de Sharon Townson
| University of Manchester Institute of Science & Technology | Doctorate Degree |
| University of Salford | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
| Royaume-Uni | 3 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 1 |
| Director/Board Member | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Health Technology |
| KYMERA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Warp Drive Bio, Inc.
Warp Drive Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Warp Drive Bio, Inc. focused on proprietary genomic technology to discover drugs of natural origin. The firm deployed proprietary platforms Genome Mining and Small Molecule Assisted Receptor Targeting (SMART) to discover and develop novel molecules addressing new pharmacologic mechanisms. The company was founded by Gregory L. Verdine, George McDonald Church, and James A. Wells in 2012 and was headquartered in Cambridge, MA. | Commercial Services |
- Bourse
- Insiders
- Sharon Townson
- Expérience
